Abstracts tagged "rheumatoid arthritis"

Abstract Number: 2157 • ACR Convergence 2023
Exploratory Analysis of the Mechanisms of Action of the Potential Analgesic Effect of Tofacitinib and Adalimumab over Placebo in Patients with Rheumatoid Arthritis: Results of a Mediation Modeling Analysis
Maxime Dougados¹, Peter C. Taylor², David Gruben³ and Meriem Kessouri⁴, ¹Rheumatology Department, Cochin Hospital; INSERM (U1153): Clinical Epidemiology and Biostatistics, University of Paris, Paris, France, ²Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ³Pfizer Inc., Groton, CT, ⁴Pfizer Inc., Paris, France
Background/Purpose: Pain is the most common symptom reported by patients (pts) with rheumatic disorders, such as RA.1 Improvement in pain with antirheumatic drugs is generally…
Abstract Number: 2174 • ACR Convergence 2023
JAK Inhibitors in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients, 55 of Baricitinib
Ana Serrano-Combarro¹, Belén Atienza-Mateo², Jesus Alejandro Valero-Jaimes³, Marta Pastor-Mena⁴, Rafael Benito Melero-Gonzalez⁵, David Castro-Corredor⁶, Maria Martin-Lopez⁷, Santos Castañeda⁸, Jesus Loarce-Martos⁹, Natalia Mena Vazquez¹⁰, Carmen carrasco-Cubero¹¹, Carolina Diez-Morrondo¹², andrea Garcia-Valle¹³, Gema Bonilla¹⁴, Juan Maria Blanco-Madrigal¹⁵, Natividad del Val del Amo¹⁶, Nuria Vegas Revenga¹⁷, Lorena Perez-Albadalejo¹⁸, Rafaela Ortega Castro¹⁹, Deseada Palma-Sanchez²⁰, Ana Maria fernandez-Ortiz²¹, Patricia Lopez-Viejo²², Maria Lopez-Lasanta²³, Marta Garijo Bufort²⁴, Ivette Casafont-Sole²⁵, Olga Maiz-Alonso²⁶, Juan Moreno-Morales²⁷, Ana Urruticoechea²⁸, Carolina Perez-Garcia²⁹, Jose Rosas³⁰, Virginia Ruiz-Esquide³¹, Delia Fernández-Lozano³², Ignacio Brana Abascal³³, Evelin Cecilia Cervantes-Perez³⁴, Julia Fernandez-Melon³⁵, Cristina Fernandez³⁶, Bryan Josue Flores Robles³⁷, Diego Ferrer³⁸ and Ricardo Blanco³⁹, ¹Hospital Universitario Marques de Valdecilla, IDIVAL, Santander, Spain, ²Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³Hospital Bidasoa, Irún, Spain, ⁴Hospital de Jerez de la Frontera, Cádiz, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ⁷Hospital 12 de Octubre, Madrid, Spain, ⁸Hospital Universitario de la Princesa, Madrid, Spain, ⁹Ramón y Cajal University Hospital, Madrid, Spain, ¹⁰IBIMA, Málaga, Spain, ¹¹Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ¹²Division of Rheumatology, Hospital de León, León, Spain, ¹³Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹⁴Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁵Division of Rheumatology, H. Universitario de Basurto, Bilbao, Spain, ¹⁶Complejo Hospitalario de Navarra, Pamplona, Spain, ¹⁷Hospital Galdakao- Usansolo, Galdakao, Spain, ¹⁸Division of Rheumatology, Hospital Universitario de Jaén, Jaén, Spain, ¹⁹Hospital Reina Sofía, Cordoba, Spain, ²⁰Hospital Rafael Mendez, Lorca, Spain, ²¹CHU Badajoz, Badajoz, Spain, ²²Division of Rheumatology, Hospital Severo Ochoa, Leganéz, Spain, ²³Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁴H. de Sagunto, Valencia, Italy, ²⁵Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁶University Hospital Donostia, San Sebastian, Spain, ²⁷Hospital Universitario Santa Lucia Cartagena, Cartagena, Spain, ²⁸Hospital Can Misses, Ibiza, Spain, ²⁹Hospital del Mar, Barcelona, Spain, ³⁰Hospital Marina Baixa, Alicante, Spain, ³¹Hospital Clinic, Rheumatology, Barcelona, Spain, ³²Hospital de Mérida, Merida, Spain, ³³Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Rheumatology, Hospital Universitario Son Espases, Palma de Mallorca, Spain, ³⁶Hospital Universitario San Juan de Alicante, Alicante, Spain, ³⁷Hospital Universitario San Pedro, Logroño, Spain, ³⁸Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁹Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain
Background/Purpose: Interstitial lung disease (ILD) is a severe extra-articular manifestation of rheumatoid arthritis (RA). Abatacept and Rituximab are the recommended drugs. JAK inhibitors (JAKi) have…
Abstract Number: 2471 • ACR Convergence 2023
Higher Pain and Functional Impairment in Erosive Hand Osteoarthritis Than in Treated Rheumatoid Arthritis: A Comparative Study Between DIGICOD and ESPOIR Cohorts
Sabryne Berkani¹, Ainhoa Aparicio Monforte², Sophie tuffet², alexandra rousseau², nathalie rincheval³, emmanuel maheu⁴, bernard combe³, Alain SARAUX⁵, Bruno Fautrel⁶, Laure Gossec⁷, Francis Berenbaum⁴, Jeremie SELLAM⁶ and alice courties⁴, ¹Sorbonne Université, Rheumatology department, (AP-HP) Saint-Antoine Hospital, Paris, France, ²Department of Clinical Pharmacology and Clinical Research Platform Paris-East (URCEST-CRC-CRB), APHP, Hôpital St Antoine, Paris, France, ³Department of Rheumatology, University of Montpellier, Montpellier, France, ⁴Sorbonne Université Assistance Publique – Hôpitaux de Paris (AP-HP), Saint-Antoine Hospital, Department of Rheumatology, Paris, France, ⁵CHU Brest, Brest, France, ⁶Sorbonne Université APHP, Paris, France, ⁷Sorbonne Université and Pitié Salpêtrière Hospital, Paris, France
Background/Purpose: Hand osteoarthritis (HOA) is considered as a less severe disease with a better functional prognosis and a lower global burden than rheumatoid arthritis (RA).…
Abstract Number: 2544 • ACR Convergence 2023
Microbial Metabolism of Methotrexate Contributes to Its Pharmacokinetics in Vivo
Diego Orellana, Mohana Mukherjee, Moriah Sandy, Peter Turnbaugh and Renuka Nayak, University of California San Francisco, San Francisco, CA
Background/Purpose: Methotrexate (MTX) is a first-line treatment drug used in rheumatoid arthritis (RA) patients. However, only 30-40% of patients tolerate the drug and achieve adequate…
Abstract Number: 0045 • ACR Convergence 2023
Discovery and Characterization of a Selective, Orally Bioavailable PAD4 Inhibitor to Target NETs Driven Autoimmune and Inflammatory Diseases
Min Yang¹, song feng¹, yuling wen¹, Xiaoming ren¹, Huijuan Li¹, lili yao¹, Zhi xie² and Wenge zhong¹, ¹Regor Therapeutics, Shanghai, China, ²Regor Pharmaceuticals, Inc., San Francisco, CA
Background/Purpose: Protein arginine deiminases (PAD) 4 is an enzyme that catalyzes the conversion of protein-embedded arginine to citrulline. It is essential for neutrophil extracellular traps…
Abstract Number: 0122 • ACR Convergence 2023
Depression, Anxiety and Post-Traumatic Stress Disorder in Association with Cardiovascular Disease Among Patients with Systemic Lupus Erythematosus and Rheumatoid Arthritis in the All of Us Research Program
Jeong Yee¹, Emily G. Oakes¹, May Choi², Candace Feldman¹, Elizabeth Karlson¹ and Karen Costenbader³, ¹Brigham and Women's Hospital, Boston, MA, ²University of Calgary, Calgary, AB, Canada, ³Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose: Cardiovascular disease (CVD) risk is increased for patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE). Mental health conditions such as depression, anxiety,…
Abstract Number: 0277 • ACR Convergence 2023
Anti-carbamylated Antibodies in Autoimmunity – Focus on Their Diagnostic and Prognostic Value: A Systematic Review and Meta-analysis
Julie Sarrand, Dorian Parisis, Muhammad Soyfoo and Paschalis Sidiras, Erasmus Hospital, Brussels, Belgium
Background/Purpose: This is the first systematic review and meta-analysis to examine the prevalence, the diagnostic and the prognostic value of anti-carbamylated protein (CarP) antibodies in…
Abstract Number: 0389 • ACR Convergence 2023
The Role of anti-CCP3 Antibodies in anti-CCP2 Antibody Negative Patients with Musculoskeletal Symptoms
Andrea Di Matteo¹, Kulveer Mankia², Leticia Garcia-Montoya², Jacqueline Nam², Sana sharrack³, Michael Mahler⁴ and Paul Emery³, ¹Polytechnic University of Marche, Jesi, Italy, ²Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom, ³Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, and NIHR Leeds Biomedical Research Centre, Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom, ⁴Werfen, San Diego, CA
Background/Purpose: To investigate, in primary care, whether testing anti-CCP3 antibodies in anti-CCP2 negative individuals with musculoskeletal (MSK) symptoms, improved the prediction of inflammatory arthritis (IA)/rheumatoid…
Abstract Number: 0406 • ACR Convergence 2023
Obesity Is a Risk Factor for Poor Response to Treatment in Early Rheumatoid Arthritis – a NORD-STAR Spin-Off Study
Violetta Dubovyk¹, Gerdur Maria Grondal², Bjorn Gudbjornsson³, Espen A Haavardsholm⁴, Marte Schrumpf Heiberg⁴, Merete Hetland⁵, Kim Hørslev-Petersen⁶, Meliha Kapetanovic⁷, Alf Kastbom⁸, John Lampa⁹, Kristina Lend¹⁰, Dan Nordstrom¹¹, Michael Nurmohamed¹², Milad Rizk¹³, Annika Söderbergh¹⁴, Till Uhlig¹⁵, Mikkel Østergaard¹⁶, Ronald van Vollenhoven¹², Anna Rudin¹⁷ and Cristina Maglio¹⁸, ¹University of Gothenburg, Gothenburg, Sweden, ²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ³Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁴Diakonhjemmet Hospital, Oslo, Norway, ⁵Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁶University of Southern Denmark, Odense, Denmark, ⁷Lund University and Skåne University Hospital, Lund, Sweden, ⁸Linköping University, Linköping, Sweden, ⁹Stockholm County, Hãsselby, Sweden, ¹⁰Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹¹Helsinki University Hospital, Helsinki, Finland, ¹²Amsterdam University Medical Centers, Amsterdam, Netherlands, ¹³Västmanlands Hospital Västerås, Västerås, Sweden, ¹⁴Örebro University Hospital, Örebro, Sweden, ¹⁵Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ¹⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ¹⁸Institute of Medicine, University of Gothenburg, Gothenburg, Sweden
Background/Purpose: Several therapeutic options are currently available to treat rheumatoid arthritis (RA); however, the response to treatment is highly variable, and not all patients achieve…
Abstract Number: 0422 • ACR Convergence 2023
Electronic Health Record-Based Machine Learning Model for Predicting Disease Activity in Patients with Rheumatoid Arthritis
Zelin Yun¹, Chun Li² and Zhanguo Li², ¹Peking University People's Hospital, Beijing, China, ²Peking University People’s Hospital, Beijing, China
Background/Purpose: Rheumatoid arthritis (RA) is one of the most prevalent chronic inflammatory diseases in which synovitis gradually leads to polyarthritis and joint destruction. Poor response…
Abstract Number: 0439 • ACR Convergence 2023
Humoral Immune Response to 13 Valent-conjugate and 23-valent Polysaccharide Pneumococcal Vaccines in RA Patients Treated with Abatacept: Results of the Open Randomized Controlled Trial VACINA (Vaccination Against Pneumococcal in Naïve Abatacept Rheumatoid Arthritis Patients)
JACQUES MOREL¹, Olivier Brocq², Cécile Gaujoux Viala³, Arnaud Constantin⁴, Slim Lassoued⁵, Emanuelle Dernis⁶, Christophe Richez⁷, Cedric Lukas⁸, Claire Daien⁹ and Claire Duflos¹⁰, ¹Protocole thérapeutique immuno-rhumatologie, Montpellier, France, ²Hospital of Princesse Grâce de Monaco, Monaco, Monaco, ³IDESP Univ Montpellier, INSERM, Rheumatology, CHU Nîmes, Montpellier, France, ⁴Teaching hospital Purpan, and University of Paul Sabatier, Toulouse, France, ⁵Hospital of Jean-Rougié, Cahors, France, ⁶CH Le Mans, Le Mans, France, ⁷Université de Bordeaux, Bordeaux, France, ⁸CHU Montpellier, Montpellier, France, ⁹University Hospital, Montpellier, France, ¹⁰CHU and University of Montpellier, Montpellier, France
Background/Purpose: To prevent infections, EULAR recommends to vaccinate RA patients against streptococcal pneumoniae. PCV13 is a T- cell dependent vaccine whereas PPSV23 induces a T-independent…
Abstract Number: 0456 • ACR Convergence 2023
The “Topics” in the Electronic Health Record of Rheumatoid Arthritis Patients Before Initiating Targeted Therapies and Association with Future Treatment Course
Jason Tang¹, Dana Weisenfeld², Kumar Dahal², Linshanshan Wang³, Clara-Lea Bonzel³, Yumeko Kawano², Gregory McDermott², Tianxi Cai⁴ and Katherine Liao², ¹Harvard College, Belmont, MA, ²Brigham and Women's Hospital, Boston, MA, ³CELEHS Lab, Cambridge, MA, ⁴Harvard T.H. Chan School of Public Health, Boston, MA
Background/Purpose: Strong clinical predictors for response to biologic and targeted synthetic disease modifying rheumatic drugs (b/tsDMARDs) in rheumatoid arthritis (RA) have yet to be identified.…
Abstract Number: 0735 • ACR Convergence 2023
Deep Immunophenotyping Reveals Circulating Activated Lymphocytes in Individuals at Risk for Rheumatoid Arthritis
Jun Inamo¹, Joshua Keegan², Alec Griffith², Tusharkanti Ghosh³, Alice Horisberger², Kaitlyn Howard², John Pulford², Ekaterina Murzin², Brandon Hancock², The Accelerating Medicines Partnership SLE/RA⁴, Marie Feser⁴, Jill Norri⁵, Anna Helena Jonsson⁶, Ye Cao⁷, William Apruzzese⁸, S. Louis Bridges⁹, Vivian Bykerk¹⁰, Susan Goodman⁹, Laura Donlin⁹, Gary S Firestein¹¹, Harris Perlman¹², Joan Bathon¹³, Laura Hughes¹⁴, Darren Tabechian¹⁵, Andrew Filer¹⁶, Costantino Pitzalis¹⁷, Jennifer Anolik¹⁵, Larry Moreland¹⁸, Joel Guthridge¹⁹, Judith James¹⁹, Michael Brenner², Soumya Raychaudhuri⁶, Jeffrey Sparks²⁰, Jennifer Seifert²¹, Michael Holer⁴, Kevin Deane⁴, James Lederer², Deepak Rao⁶ and Fan Zhang²², ¹University of Colorado School of Medicine, Aurora, CO, ²Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ³School of Public Health, University of Colorado, Anschutz Medical Campus, Aurora, CO, ⁴University of Colorado Anschutz Medical Campus, Aurora, CO, ⁵Colorado School of Public Health, Denver, CO, ⁶Brigham and Women's Hospital, Boston, MA, ⁷Brigham and Women's Hospital, Boston, MA, ⁸Accelerating Medicines Partnership® Program: Rheumatoid Arthritis and Systemic Lupus Erythematosus (AMP® RA/SLE) Network, Boston, MA, ⁹Hospital for Special Surgery, New York, NY, ¹⁰Department of Rheumatology, Hospital for Special Surgery, New York, NY, ¹¹Department of Medicine, University of California San Diego, La Jolla, CA, ¹²Northwestern University, Chicago, IL, ¹³Columbia University, New York, NY, ¹⁴University of Alabama at Birmingham Medicine, Birmingham, AL, ¹⁵University of Rochester Medical Center, Rochester, NY, ¹⁶University of Birmingham, Birmingham, United Kingdom, ¹⁷Queen Mary University of London, London, United Kingdom, ¹⁸University of Colorado, Denver, CO, ¹⁹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²⁰Division of Rheumatology, Inflammation, and Immunity, Brigham and Women’s Hospital and Harvard Medical School, Boston, MA, ²¹The Accelerating Medicines Partnership RA/SLE Network, ²²University of Colorado, Aurora, CO

Background/Purpose: Rheumatoid arthritis (RA) is a systemic autoimmune disease with currently no effective prevention strategies. Single-cell technologies have been used to investigate established RA heterogeneity…
Abstract Number: 0798 • ACR Convergence 2023
A Novel 3D Model of Rheumatoid Arthritis Synovial Tissue Incorporating Fibroblasts, Endothelial Cells and Macrophages
Eva Philippon¹, Lisanne van Rooijen¹, Jan Piet van Hamburg¹, Fatemeh Khodadust¹, Conny Van der Laken² and Sander Tas³, ¹Amsterdam University Medical Centers, Amsterdam, Netherlands, ²Amsterdam UMC - location VUMC, Amsterdam, Netherlands, ³Amsterdam UMC, locatie AMC, Utrecht, Netherlands
Background/Purpose: Rheumatoid Arthritis (RA) is a progressive and systemic autoimmune disorder associated with chronic and destructive inflammation of the joints. The hallmarks of RA are…
Abstract Number: 0967 • ACR Convergence 2023
Overall Survival in Patients with versus Without Rheumatoid Arthritis Initiating Immune Checkpoint Inhibitors for Metastatic Non Small Cell Lung Cancer
Deanna Jannat-Khah¹, Jeffrey R Curtis², Fenglong Xie³, Ashish Saxena⁴ and Anne Bass⁵, ¹Hospital For Special Surgery, New York, NY, ²Division of Clinical Immunology and Rheumatology, University of Alabama, Birmingham, AL, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Weill Cornell Medicine, New York, NY, ⁵Hospital for Special Surgery, Weill Cornell Medicine, New York, NY
Background/Purpose: Immune checkpoint inhibitors (ICI) increase one-year survival in metastatic non-small cell lung cancer (mNSCLC) from 49% to 69% with chemotherapy-based regimens. Patients with rheumatoid…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].